Efinopegdutide
Phase 2CompletedDevelopment Stage
Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
Jul 29, 2024 → Jun 27, 2025
About Efinopegdutide
Efinopegdutide is a phase 2 stage product being developed by Merck for Metabolic Dysfunction-Associated Steatotic Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT06482112. Target conditions include Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease.
What happened to similar drugs?
19 of 20 similar drugs in Metabolic Dysfunction-Associated Steatotic Liver Disease were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06482112 | Phase 2 | Completed |
| NCT06052566 | Phase 1 | Completed |
Competing Products
20 competing products in Metabolic Dysfunction-Associated Steatotic Liver Disease